Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys-mechanism and monitoring

Clinical Cancer Research

Volumn 23, Issue 7, 2017, Pages 1760-1770

  Guffroy, Magali ^a   Falahatpisheh, Hadi ^a   Biddle, Kathleen ^a   Kreeger, John ^a   Obert, Leslie ^a   Walters, Karen ^a   Goldstein, Richard ^a   Boucher, Germaine ^a   Coskran, Timothy ^a   Reagan, William ^a   Sullivan, Danielle ^a   Huang, Chunli ^a   Sokolowski, Sharon ^a   Giovanelli, Richard ^a   Gerber, Hans Peter ^a   Finkelstein, Martin ^a   Khan, Nasir ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; HYALURONIC ACID; MONOCLONAL ANTIBODY; PF 0259; UNCLASSIFIED DRUG; AMINOGLYCOSIDE; ANTIBODY CONJUGATE; CALICHEAMICIN T; ENEDIYNE; GEMTUZUMAB; INOTUZUMAB OZOGAMICIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPSY; BLOOD LEVEL; BONE MARROW; CONTROLLED STUDY; DISEASE MARKER; HISTOPATHOLOGY; HYALURONIC ACID BLOOD LEVEL; LIVER ATROPHY; LIVER CELL; LIVER INJURY; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MACACA FASCICULARIS; MALE; MEGAKARYOCYTE; MICROANGIOPATHY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; SINUSOIDAL ENDOTHELIAL CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; ENDOTHELIUM CELL; HUMAN; LIVER; NEOPLASM; PATHOLOGY; TOXIC HEPATITIS;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMICAL AND DRUG INDUCED LIVER INJURY; ENDOTHELIAL CELLS; ENEDIYNES; HUMANS; HYALURONIC ACID; IMMUNOCONJUGATES; LIVER; MACACA FASCICULARIS; NEOPLASMS; THROMBOCYTOPENIA;

EID: 85016983894     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0939     Document Type: Article

References (45)

1. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011;17:6417-27.
2. Ehninger A, Kramer M, Röllig C, Thiede C, Bornhäuser M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J 2014;4:e218.
3. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6.
4. US Food and Drug Administration. Pfizer voluntarily withdraws cancer treatment Mylotarg from US market. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm216448.htm. Released: June 21, 2010.
5. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854-60.
6. McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007;31:599-604.
7. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with denovo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508-16.
8. Walter RB, Medeiros BC, Gardner KM, Orlowski KF, Gallegos L, Scott BL, et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Haematologica 2014;99:54-9.
9. Tu X, LaVallee T, Lechleider R. CD22 as a target for cancer therapy. J Exp Ther Oncol 2011;9:241-8.
10. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al. et al. Efficacy and safety of Gemtuzumab Ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19: 3244-54.
11. Ohanian M, Kantarjian H, Guy D, Thomas D, Jabbour E, O'Brien S. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther 2015;4:601-11.
12. Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013;163:444-57.
13. Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-52.
14. Advani AS, Stein AS, Kantarjian HM, Shustov AR, DeAngelo DJ, Ananthakrishnan R, et al. A Phase II study of weekly inotuzumab ozogamicin (InO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage. In: Proceedings of the 56th Annual Meeting of the American Society of Hematology; 2014 Dec 6-9; San Francisco, CA. Washington, DC: ASH; 2014. Abstract nr 2255.
15. Maniecki MB, Hasle H, Bendix K, Møller HJ. Is hepatotoxicity in patients treated with gemtuzumab ozogamicin due to specific targeting of hepatocytes? Leuk Res 2011;35:e84-6.
16. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99:2310-4.
17. Narita M, Oussoultzoglou E, Chenard MP, Fuchshuber P, Rather M, Rosso E, et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol 2012;19:2230-7.
18. Moroni M, Lombardini E, Salber R, Kazemzedeh M, Nagy V, Olsen C, et al. Hematological changes as prognostic indicators of survival: Similarities between Gottingen Minipigs, Humans, and other large animal models. PLoS One 2011;6:e25210.
19. Neumüller J, Meisslitzer-Ruppitsch C, Ellinger A, Pavelka M, Jungbauer C, Renz R, et al. Monitoring of platelet activation in platelet concentrates using transmission electron microscopy. Transfus Med Hemother 2013;40: 101-7.
20. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010;56:430-9.
21. van den Broek MA, Vreuls CP, Winstanley A, Jansen RL, van Bijnen AA, Dello SA, et al. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 2013;20:1462-9.
22. Lee JH, Lee KH, Lee JH, Kim S, Seol M, Park CJ, et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol 2002;118:1087-94.
23. Eriksson S, Fraser JR, Laurent TC, Pertoft H, Smedsrød B. Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res 1983;144:223-8.
24. Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic venoocclusive disease). J Clin Exp Hepatol 2014;4:332-46.
25. Provan D, Newland AC, MacCallum PK. Acquired disorders affecting megakaryocytes and platelets. In: Porwit A, McCullough J, Erber WN, editors. Blood and bone marrow pathology. Churchill Livingstone Elsevier 2011; p. 523-45.
26. Tajima H, Ohta T, Miyashita T, Nakanuma S, Matoba M, Miyata T, et al. Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver. Mol Clin Oncol 2015;3:555-8.
27. Nishigori N, Matsumoto M, Koyama F, Hayakawa M, Hatakeyayama K, Ko S, et al. von Willebrand Factor-rich platelet thrombi in the liver cause sinusoidal obstruction syndrome following oxaliplatin-based chemotherapy. PLoS One 2015;10:e0143136.
28. Nakanuma S, Miyashita T, Hayashi H, Tajima H, Takamura H, Makino I, et al. Extravasated platelet aggregation in liver zone 3 is associated with thrombocytopenia and deterioration of graft function after living-donor liver transplant. Exp Clin Transplant 2015;13:556-62.
29. Rio B, Andreu G, Nicod A, Arrago JP, Dutrillaux F, Samama M, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986;67:1773-6.
30. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2015;50: 781-9.
31. Kishi Y, Numano F. In vitro study of vascular endothelial injury by activated platelets and its prevention. Atherosclerosis 1989;76:95-101.
32. Hubert C, Sempoux C, Humblet Y, van den Eynde M, Zech F, Leclercq I, et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB 2013; 15:858-64.
33. Nakanuma S, Miyashita T, Hayashi H, Tajima H, Takamura H, Tsukada T, et al. Extravasated platelet aggregation in liver zone 3 may correlate with the progression of sinusoidal obstruction syndrome following living donor liver transplantation: a case report. Exp Ther Med 2015;9:1119-24.
34. Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol 2001;13: 791-801.
35. DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology 2015;61:1740-6.
36. Miller-Kasprzak E, Jagodziński PP. Endothelial progenitor cells as a new agent contributing to vascular repair. Arch Immunol Ther Exp 2007;55: 247-59.
37. Qiao J, Qi K, Chu P, Mi H, Yang N, Yao H, et al. Infusion of endothelial progenitor cells ameliorates liver injury in mice after haematopoietic stem cell transplantation. Liver Int 2015;35:2611-20.
38. Sartori MT, Cesaro S, Peruzzo M, Messina C, Saggiorato G, Calore E, et al. Contribution of fibrinolytic tests to the differential diagnosis of venoocclusive disease complicating pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer 2012;58:791-7.
39. Fried MW, Duncan A, Soroka S, Connaghan DG, Farrand A, Peter J, et al. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 2001;27: 635-9.
40. Guechot J, Poupon RE, Poupon R. Serum hyaluronan as a marker of liver fibrosis. J Hepatol 1995;22:103-6.
41. Nyberg A, Engstrom-Laurent A, Loof L. Serum hyaluronidate in primary biliary cirrhosis: a biochemical marker for progressive liver damage. Hepatology 1988;8:142-6.
42. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. JClin Oncol 2010;28:2698-704.
43. Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, et al. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2012;70:591-601.
44. Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW Jr, Chalasani N, et al. Nodular regenerative hyperplasia after treatment with trastuzumab emtansine. J Clin Oncol 2016;34:e9-e12.
45. Yan H, Endo Y, Shen Y, Rotstein D, Dokmanovic M, Mohan N, et al. Adotrastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity. Mol Cancer Ther 2016;15: 480-90.